deltatrials
Terminated PHASE3 NCT00122980

Stroke With Transfusions Changing to Hydroxyurea

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Conditions Anemia, Sickle Cell Cerebrovascular Accident Hematologic Diseases Hemochromatosis
Interventions Hydroxyurea Iron Chelation Phlebotomy Red Cell Transfusions
Updated 8 times since 2017 Last updated: Jan 14, 2013 Started: Oct 31, 2006 Primary completion: Jun 30, 2010 Completion: Dec 31, 2010

A PHASE3 clinical study on Anemia, Sickle Cell and Cerebrovascular Accident, this trial is terminated or withdrawn. The trial is conducted by National Heart, Lung, and Blood Institute (NHLBI) and has accumulated 8 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  4. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE3

  5. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE3

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE3

  2. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE3

  3. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE3

    First recorded

Oct 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Heart, Lung, and Blood Institute (NHLBI)
  • St. Jude Children's Research Hospital
Data source: St. Jude Children's Research Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States, Birmingham, United States, Boston, United States, Brooklyn, United States, Charleston, United States, Chicago, United States, Cincinnati, United States, Dallas, United States, Detroit, United States, Greenville, United States and 16 more location s